Astrazeneca obtains first approval for Seloken Zok for the treatment of heart failure
® ASTRAZENECA OBTAINS FIRST APPROVAL FOR SELOKEN ZOK FOR THE TREATMENT OF HEART FAILURE ® AstraZeneca today announced that the beta blocker, Seloken ZOK, has gained its first approval for the treatment of heart failure, an important extension to the existing range of cardiovascular indications for ® Seloken ZOK which include angina, hypertension and post-myocardial infarction. The licence approval was granted in Denmark and the company expects to gain further approvals elsewhere in Europe later this year. ® The new indication for Seloken ZOK (metoprolol CR/XL; controlled release/extended